Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
312
312 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- BEAM-101Phase 21 trial
Beam Therapeutics Inc. · Sickle Cell Disease
- BEAM-201Phase 21 trial
Beam Therapeutics Inc. · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- BG1805Phase 21 trial
Guangzhou Bio-gene Technology Co., Ltd · Leukemia, Myeloid, Acute
- BI-1808Phase 21 trial
BioInvent International AB · Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma
- BMS-986458Phase 21 trial
Bristol Myers Squibb · Relapsed/Refractory Non-Hodgkin Lymphoma
- BMS-986470Phase 21 trial
Bristol Myers Squibb · Anemia, Sickle Cell, Healthy Volunteers
- BosmolisibBR101801Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Peripheral T Cell Lymphoma
- BP1001Phase 21 trial
Bio-Path Holdings, Inc. · Acute Myeloid Leukemia (AML)
- BRL-101Phase 21 trial
Bioray Laboratories · Beta-Thalassemia
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CART84Phase 21 trial
Gyala Therapeutics · Acute Myeloblastic Leukaemia, Leukemia, T-Cell
- CD38Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
- CFI-400945Phase 21 trial
Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- CK0801Phase 21 trial
Cellenkos, Inc. · Aplastic Anemia
- CLN-049Phase 21 trial
Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
- CSL889Phase 21 trial
CSL Behring · Sickle Cell Disease Vaso-occlusive Crisis
- CT071Phase 21 trial
CARsgen Therapeutics Co., Ltd. · Multiple Myeloma, Primary Plasma Cell Leukemia
- CTS3497Phase 21 trial
CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma
- CTX-712Phase 21 trial
Chordia Therapeutics, Inc. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
- Debio 1562MPhase 21 trial
Debiopharm International SA · Acute Myeloid Leukemia
- DISC-3405Phase 21 trial
Disc Medicine, Inc · Polycythemia Vera (PV)
- DS3790aPhase 21 trial
Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
- EMB07Phase 21 trial
Shanghai EpimAb Biotherapeutics Co., Ltd. · Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07
- EO2463Phase 21 trial
Enterome · Follicular Lymphoma, Marginal Zone Lymphoma
- EP0042Phase 21 trial
Ellipses Pharma · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial
Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma
- EX103Phase 21 trial
Guangzhou Excelmab Inc. · CD20-positive Non-Hodgkin Lymphoma
- Extended PhasePhase 21 trial
Chengdu Zenitar Biomedical Technology Co., Ltd · Polycythemia Vera (PV)
- F182112Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
- GB2064Phase 21 trial
Galecto Biotech AB · Myelofibrosis
- GPC-100Phase 21 trial
GPCR Therapeutics, Inc. · Multiple Myeloma
- GSK3174998Phase 21 trial
GSK · Multiple Myeloma
- GSK5926371Phase 21 trial
GSK · Lymphoma, Non-Hodgkin
- GT719Phase 21 trial
Grit Biotechnology · Hematological Malignancy (Leukemia- Lymphoma)
- HDM2005Phase 21 trial
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Diffuse Large B Cell Lymphoma (DLBCL)
- HDP-101Phase 21 trial
Heidelberg Pharma AG · Multiple Myeloma, Plasma Cell Disorder
- HEC53856Phase 21 trial
Sunshine Lake Pharma Co., Ltd. · Chemotherapy-induced Anemia, Non-Myeloid Malignancy
- HMB-002Phase 21 trial
Hemab ApS · Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2
- HMPL-689Phase 21 trial
Hutchmed · Relapsed/Refractory Lymphoma
- HP-002Phase 21 trial
Shanghai Helioson Pharmaceutical Co., Ltd. · B-Cell Non-Hodgkin Lymphoma
- HuL001Phase 21 trial
HuniLife Biotechnology, Inc. · Multiple Myeloma Refractory
- HX111Phase 21 trial
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. · Solid Tumor and Lymphoma
- ICP-490Phase 21 trial
Beijing InnoCare Pharma Tech Co., Ltd. · Relapsed or Refractory Non-Hodgkin Lymphoma
- IDP-023Phase 21 trial
Indapta Therapeutics, INC. · NHL, Multiple Myeloma, Blood Cancer
- IMT-009Phase 21 trial
Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
- INCA000585Phase 21 trial
Incyte · Immune Thrombocytopenia
- ITU512Phase 21 trial
Novartis · Sickle Cell Disease
- JBI-802Phase 21 trial
Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.